Gene Therapy Market: Revolutionizing Medicine with Tailored Genetic Treatments

The gene therapy market is witnessing unprecedented growth, driven by advancements in personalized medicine and innovative technologies to address genetic disorders. Below are the key factors fuelling this dynamic market:

1. Rising Demand for Tailored Therapies

• Focus on Genetic Disorders: Gene therapy provides a revolutionary approach to treating diseases caused by genetic mutations, offering precision and effectiveness.
• Mechanism: By replacing defective genes with functional ones, gene therapy targets diseases at the cellular level, delivering long-lasting therapeutic effects.

2. Innovative Therapeutic Tools and Techniques

• Use of Molecular Carriers: Viral and non-viral vectors serve as carriers for delivering functional genes, enhancing treatment efficiency.
• Gene Editing Advancements: Cutting-edge tools like CRISPR-Cas9 are accelerating the development of next-generation gene-based therapies.

3. Milestones in Gene Therapy Approvals

• Pioneering Approvals:
• Tisagenlecleucel (2017): The first FDA-approved gene therapy for relapsed or refractory pediatric and young-adult B-cell acute lymphoblastic leukemia.
• Libmeldy™ (2020): An ex vivo gene therapy approved to treat metachromatic leukodystrophy.
• Pipeline Therapies: Over 200 gene therapies are currently in phase II and phase III clinical trials, indicating a robust pipeline.

4. Increased R&D Investments

• Industrial Participation: Major stakeholders are ramping up research and development (R&D) to create advanced therapies.
• Next-Generation Therapies: The focus is on developing therapies with enhanced efficacy and safety profiles, ensuring broader adoption in clinical settings.

Market Outlook

Ongoing advancements in gene therapy techniques, coupled with increasing investments in research, are anticipated to propel the gene therapy market to new heights. With a strong clinical pipeline and growing regulatory support, the future of medicine is set to be transformed by gene-based treatments.

Explore how gene therapy is shaping the future of healthcare by offering hope for untreatable genetic disorders.

You Can Download Free Sample PDF Copy Of This Report At:

https://www.rootsanalysis.com/reports/gene-therapy-market-3rd-edition-2019-2030/request-sample.html

Key Report Takeaways

⬝      Over 1,150 gene therapy candidates are currently being investigated across different stages of development for the treatment of a myriad of disease indications; to date, 11 gene therapies have been commercialized.

⬝      More than 70% of the therapies are currently in the early stages of development; close to 80% of therapies being evaluated in late-stage studies (phase II and above) use viral vectors for delivery of the targeted gene.

⬝      Start-ups are spearheading innovation in the gene therapy domain; the valuation of a start-up is not solely dependent on profits, instead, it depends on experience and amount invested by industry stakeholders.

⬝      In order to tap into the lucrative opportunity associated with gene therapies, big pharma players have adopted various approaches, from proprietary product development to strategic investments, to advance their portfolios.

⬝      Rising interest in this domain is reflected in the number of mergers and acquisitions reported in the last few years; 50% of such initiatives were focused on gaining access to novel platforms or therapeutic area consolidation.

⬝      Treatment cost is one of the major concerns in this market; we anticipate more affordable pricing and reimbursement strategies to evolve in due course.

⬝      To monetize the full potential, stakeholders are already actively exploring diverse commercialization strategies across different stages of a product’s launch cycle.

⬝      The market opportunity associated with gene therapies is anticipated to witness an annualized growth of nearly 18% over the next decade.

⬝      In the long term, the projected opportunity is anticipated to be well distributed across different therapeutic areas, routes of administration, and key geographical regions.

Competitive Landscape of the Gene Therapy Market

Currently, the market landscape features over 250 gene therapy companies that are actively engaged in the production of various early and late-stage gene therapies across the globe. Overall, the gene therapy market is well fragmented and features several industrial players and industrial stakeholders who are actively investing in research and development initiatives for the production of gene therapies. To support the growing demand, several companies developing gene therapies are currently undergoing different collaborations to advance their research for next-generation gene-based therapies. However, the primary focus of such consolidation efforts will be on expanding the existing development efforts. The ongoing collective efforts of the companies and rising demand for highly efficient single-dose gene-based therapeutics are anticipated to drive the market during the forecast period.

Gene Therapy Market Geographical Region Outlook

Based on the geographical region, the gene therapy market is segmented into North America, Europe, Asia-Pacific, and the rest of the world. Currently, North America leads the market, and the trend remains unchanged during the forecast period. In North America, the gene therapy market is estimated to hold 59.5% of the share by 2035. In Asia-Pacific, the market is estimated to grow at a higher CAGR of 27.1% during the forecast period.

Gene Therapy Market Players

Examples of the key companies engaged in the gene therapy market (which have also been profiled in the market report; the complete list of the companies is also included in the full report) include:

⬝      Amgen

⬝      AnGes

⬝      Biogen

⬝      Bluebird bio

⬝      Dendreon Pharmaceuticals

⬝      Enzyvant Therapeutics 

⬝      Kite Pharma 

⬝      Novartis AG

⬝      Oxford Biomedica

⬝      UniQure NV

⬝      Spark Therapeutics, Inc

⬝      SIBONO

⬝      Shanghai Sunway Biotech 

In recent years, gene therapies have catered to the attention of the leading industrial players owing to their significance in the treatment of genetic disorders. Considering these significance, several gene therapy market players increase their research and development activities to enhance the development of advanced gene-based therapeutics.

⬝      In August 2023, TSHA-102, developed by Taysha Gene Therapies, received fast-track designation approval from the FDA for the treatment of patients suffering from Rett Syndrome.

⬝      In August 2023, Xcell Biosciences and LabCorp inked a collaboration deal for the development and validation of cell and gene-based therapies.

⬝      In May 2023, Ray Therapeutics successfully closed around USD 100 million in a series A funding round, and the company will utilize these funds to enhance the development of optogenetic gene therapies.

To get market data, market insights, financial statements, and a comprehensive analysis of the gene therapy market, please contact sales@rootsanalysis.com

Gene Therapy Market Segments

Based on the research report, Roots Analysis has been segmented based on the type of therapy, type of gene therapy delivery method, type of vector used, target therapy areas, route of administration, end user, and key geographical regions.

▪          Gene Therapy Market, Based on the Type of Therapy

⬝    Gene Augmentation

⬝    Oncolytic Viral Therapy

⬝    Immunotherapy

⬝    Others

▪          Gene Therapy Market, Based on the Type of Gene Delivery Method

⬝    Ex vivo method

⬝    In vivo method

▪          Gene Therapy Market, Based on Type of Vector Used

⬝    Adeno-associated Virus

⬝    Adenovirus

⬝    Herpes Simplex Virus

⬝    Lentivirus

⬝    Non-Viral Vectors

⬝    Retrovirus

⬝    Others

▪          Gene Therapy Market, Based on the Target Therapeutic Areas

⬝    Cardiovascular Diseases

⬝    Dermatological Diseases

⬝    Genetic Diseases

⬝    Hematological Diseases

⬝    Infectious Diseases

⬝    Metabolic Diseases

⬝    Muscle-Related Diseases

⬝    Oncological Diseases

⬝    Ophthalmic Diseases

⬝    Others

▪          Gene Therapy Market, Based on the Route of Administration

⬝    Intraarticular

⬝    Intracerebral

⬝    Intracoronary

⬝    Intradermal

⬝    Intralesional

⬝    Intramuscular

⬝    Intrapleural

⬝    Intrathecal

⬝    Intratumoral

⬝    Intravenous

⬝    Intravesical

⬝    Intravitreal

⬝    Subretinal

⬝    Topical

⬝    Others

▪          Gene Therapy Market, Based on the Geographical Region

⬝    North America

⬝    Europe

⬝    Asia-Pacific

⬝    Rest of the World

You Can View the Complete Report on the Gene Therapy Market Online by Clicking On the Given Link

https://www.rootsanalysis.com/reports/gene-therapies-market/268.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (415) 800 3415